ContractDevelopment and License Agreement • August 8th, 2008 • Aradigm Corp • Electromedical & electrotherapeutic apparatus • New York
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • August 8th, 2008 • Aradigm Corp • Electromedical & electrotherapeutic apparatus
This First Amendment to the Development and License Agreement (the “First Amendment”) is made and entered into effective as of October 22, 2001 (the “Effective Date”), by and between Novo Nordisk A/S, Novo Allé DK-2880 Bagsværd, Denmark (“Novo Nordisk”), and Aradigm Corporation, 3929 Point Eden Way, Hayward, California 94545 (“Aradigm”). Novo Nordisk and Aradigm may be referred to herein as a “Party” or, collectively, as “Parties”.
